ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)
Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021
![Reuters logo](/images/reuters.jpg)